We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) ...
People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE ...
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...
Use intravascular lithotripsy as an option to treat calcified coronary arteries during percutaneous coronary intervention with standard arrangements in place for clinical governance, consent and audit ...
There is a commercial access agreement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact [email protected] ...
Optimised final draft guidance published today recommends 12 SQ-HDM SLIT, also known as Acarizax and made by ALK-Abello, as an option for treating persistent moderate to severe house dust mite ...
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...
A list of downloadable documents created during development.
Pembrolizumab (Keytruda, Merck Sharp & Dohme) is indicated for 'the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and ...
NICE announces proposals to transform its HealthTech programme to drive more technology into the NHS
Consultation launches on the biggest shake-up of NICE's HealthTech programme to date. More innovative healthcare technologies could soon be adopted by the NHS under reforms proposed today by NICE.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback